Tilray Expands Medical Cannabis Product Offering in Australia – Yahoo Finance

Share Article

New Tilray Branded and GMP-Certified 15g Medical Cannabis Whole Flower Now Available for Patients Under Australia’s TGA Special Access and Authorized Prescriber Scheme

Company Launches Online Medical Cannabis Education Platform for Healthcare Professions in Australia and New Zealand
NEW YORK and SYDNEY, Australia, Jan. 25, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for healthcare providers.
Denise Faltischek, Head of International and Chief Strategy Officer, said, “Tilray is transforming the industry globally with our highly scalable footprint and portfolio of diverse cannabis products. As medical cannabis demand increases worldwide, we remain committed to providing healthcare professionals and patients with safe and reliable access to the highest-quality medical cannabis products.” Ms. Faltischek continued, “After listening to patient feedback and leveraging learnings from our operations in Germany, we are excited to be introducing new products in Australia that meet consumer needs.”
Tilray's product offering in Australia approved under the Therapeutic Goods Administration (TGA) Special Access and Authorized Prescriber Scheme is centered around its whole flower options ranging from balanced 1:1 whole flower (THC 10 CBD 10), including mid-range (17), and high THC (25) varieties of 15g bag GMP-Certified medical cannabis whole flower.
George Polimenakos, General Manager, Tilray Australia, and New Zealand, said, "We are committed to providing reliable access to patients in need with pharmaceutical-grade medical cannabis products and are pleased to be expanding our medical cannabis offerings in Australia." Mr. Polimenakos continued, “On a related note, cannabis education is paramount to everything we do and are therefore excited to offer healthcare professionals with the tools they need to learn about cannabis through our new e-learning platform.”
Tilray’s new medical cannabis educational platform for healthcare professionals is built on the importance of understanding the benefits derived from medical cannabis use. To date, Tilray has successfully introduced multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of health care practitioners in 2021.
In addition to supplying hospitals and pharmacies, Tilray is a proud partner with several leading research institutions, including the Murdoch Children's Research Institute in Australia, studying the effectiveness of Tilray medical cannabis as a treatment for pediatric patients with Intellectual Disabilities suffering from Severe Behavioral Problems; a clinical trial in partnership with The Government of New South Wales and University of Sydney Chris O'Brien Lifehouse to develop a novel treatment for chemotherapy-induced nausea, and a study led by the University of Sydney examining the effects of driving under the influence of cannabis.
Today, Tilray is one of the leading providers of GMP-certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers across the globe.
For more information about Tilray medical cannabis in Australia and New Zealand, visit: https://www.tilray.com.au/
For more information about the Tilray medicinal cannabis workshops in Australia, visit: https://tilray.medihuanna.com/
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: ; the Company’s ability to commercialize new and innovative products worldwide, including in Australia; expectations regarding worldwide medical cannabis demand; and expectations regarding regulatory approval and commercialization of medical cannabis products. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Contacts:
Tilray Global:
Berrin Noorata
[email protected]
Investors
Raphael Gross
203-682-8253
[email protected]

On yet another "red" day for stock markets, marijuana investors saw their stocks tumble right along with the rest of the Nasdaq. In a press release early this morning, Hexo gave investors an update on its strategic plan entitled "The Path Forward," explaining how Hexo — shares of which traded above $30 just a couple of years ago, but now fetch just $0.50 — intends to regain its mojo and get its share price moving higher once again. New product launches appear key to Hexo's plan, as the company launches sales of a "transdermal cream and a CBD-forward body lotion," and also a new line of "gummy confection called Redebles."
The marijuana industry witnessed higher sales during the pandemic as many states legalized cannabis. As with any evolving industry, the cannabis industry is also facing setbacks due to delays in legalization reforms at the federal level. Nevada-based Planet 13 Holdings (OTC: PLNH.F), a vertically integrated cannabis producer, might be a smaller company by market cap, but it is playing a serious game.
In recent months, financially embattled real estate developer Nile Niami has been much in the headlines, primarily thanks to “The One” — the biggest and baddest mansion Los Angeles has ever seen. That $295 million project, now 10 years into construction and still unfinished, remains scheduled to hit auction blocks within the next few weeks. […]
Fire & Flower Holdings Corp. ("Fire & Flower" or the "Company") (TSX: FAF) (OTCQX: FFLWF), a leading, technology-powered, cannabis retailer, today announced the Company has completed the acquisition of Pineapple Express Delivery Inc. ("Pineapple Express Delivery" or "PED"), a leading logistics technology company offering compliant and secure delivery services for controlled substances and regulated products, including transportation and delivery of medical and recreational products in Ontario, M
Leading Li-Metal battery manufacturer SES Holdings going public via SPAC merger SES merging with Ivanhoe Capital Acquisition Corp. (NYSE: IVAN) SES partnered with Honda, General Motors and Hyundai in […]
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both…
Medicibis ("Mendo"), a Canadian licensed producer and owner of www.mendocannabis.ca, an online portal for medical patients that ships nationwide, announced today it reached an agreement with Shelter Cannabis to ease patient transition as Agro-Greens, operator of Shelter Market, have decided to close their medical cannabis site.
These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.
Emergency medicine physician Dr. Hiral Tipirneni joins Yahoo Finance Live to discuss Omicron hospitalizations, COVID-19 vaccines, as well as two cases of a subvariant of Omicron, called BA.2,  confirmed in Washington, D.C.
Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.
One day after the U.S. Food and Drug Administration said it's halting the use of antibody drugs as COVID-19 treatments because they don't work on the highly contagious omicron variant, Pfizer and German partner BioNTech announced they are launching a trial to evaluate an omicron-based vaccine in healthy adults aged 18 to 55.
Gregory Zuckerman, author of ‘A Shot to Save the World’, joins Yahoo Finance's Editor-in-Chief, Andy Serwer, for a discussion about what COVID-19 will look like in the future.
Doctors told Yahoo Finance that three primary factors are contributing to the booster drive's slowdown.
The color of your mucus can reveal some surprising things about your health. Here's what your mucus color means, according to experts.
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD). Following the Company's submission of Phase 2 data and the chronic toxicology data in animals, the Company requested directions to further develop Buntanetap in PD. The FDA guided initiating the Phase 3 clinical studies of Buntanetap for PD parallel w
Florida Gov. Ron DeSantis is charging that the White House is withholding a COVID-19 treatment that could save lives in a state that has already lost 64,000 to the pandemic, even though medical experts have deemed the therapy ineffective against the variant currently dominant in the United States.
Dr. Michael Saag, associate dean for global health at University of Alabama-Birmingham, joins Yahoo Finance Live to discuss the importance of vaccine shots and how misinformation is impacting people's perception of the severity of COVID-19.
Federal officials are working with CVS, Costco, Walgreens and more to bring free N95 masks in varying sizes to California stores this week.
With Omicron still spiking around the U.S. Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allergy and Infectious Diseases, predicted almost everyone will catch it at some point. "I think, in many respects, omicron, with its extraordinary, unprecedented degree of efficiency of transmissibility, will, ultimately, find just about everybody," Fauci told the Center for Strategic&International Studies. Although Omicron is extremely contagiou
‘No beds for your stroke, no beds for your heart attack, no beds for your car crash, no beds for your sick child’

source

You might also like

Surviving 2nd wave of corona
COVID-19

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort

@voguewellness